Fosigotifator did not demonstrate a significant effect on disease progression, combining function and mortality measures, in either the primary or the exploratory high-dose groups.
Secondary endpoints, including the revised ALS functioning rating scale, respiratory function and health-related quality of life also showed no statistically significant improvement compared to the placebo. However, a slight signal was observed in muscle strength, with slower deterioration in both upper and lower extremities for patients in the high-dose group.
Despite the negative trial outcome for ALS, fosigotifator is still being studied for other conditions, including vanishing white matter disease and major depressive disorder.
Becker’s 3rd Annual Fall Chief Pharmacy Officer Summit is the top tier event that the people leading the future of pharmacy convene. This 3-day event is built specifically for Chief Pharmacy Officers and senior pharmacy leaders. The sessions examine the workforce, financial and clinical priorities shaping pharmacy today. Becker’s is where candid discussions flourish and new ideas thrive. Becker's 3rd Annual Fall Chief Pharmacy Officer Summit
